Details

Autor(en) / Beteiligte

• Cannon, Ashley
• McMillan, Olivia
• Kelley, Whitley V.
• East, Kelly M.
• Cochran, Meagan E.
• Miskell, Edrika L.
• Moss, Irene P.
• Garner‐Duckworth, Sherilyn
• Redden, David T.
• Might, Matthew
• Barsh, Gregory S.
• Korf, Bruce R.

Titel

Medical and psychosocial outcomes of state‐funded population genomic screening

Ist Teil von

• Clinical genetics, 2023-10, Vol.104 (4), p.434-442

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• As the uptake of population screening expands, assessment of medical and psychosocial outcomes is needed. Through the Alabama Genomic Health Initiative (AGHI), a state‐funded genomic research program, individuals received screening for pathogenic or likely pathogenic variants in 59 actionable genes via genotyping. Of the 3874 eligible participants that received screening results, 858 (22%) responded to an outcomes survey. The most commonly reported motivation for seeking testing through AGHI was contribution to genetic research (64%). Participants with positive results reported a higher median number of planned actions (median = 5) due to AGHI results as compared to negative results (median = 3). Interviews were conducted with survey participants with positive screening results. As determined by certified genetic counselors, 50% of interviewees took appropriate medical action based on their result. There were no negative or harmful actions taken. These findings indicate population genomic screening of an unselected adult population is feasible, is not harmful, and may have positive outcomes on participants now and in the future; however, further research is needed in order to assess clinical utility. Population genomic screening for a variety of medically actionable conditions may have personal and clinical utility for participants and does not appear to have a negative impact on emotional wellbeing.